Publications 2024

Gorodetska I, Offermann A, Püschel J, Lukiyanchuk V, Gaete D, Kurzyukova A, Freytag V, Haider MT, Fjeldbo CS, Di Gaetano S, Schwarz FM, Patil S, Borkowetz A, Erb HHH, Baniahmad A, Mircetic J, Lyng H, Löck S, Linge A, Lange T, Knopf F, Wielockx B, Krause M, Perner S, Dubrovska A (2024)
ALDH1A1 drives prostate cancer metastases and radioresistance by interplay with AR- and RAR-dependent transcription
Theranostics, 14 (2), 714-737
DOI 10.7150/thno.88057, PubMed 38169509

Lukovic J, Pintilie M, Han K, Fyles AW, Bruce JP, Quevedo R, Pugh TJ, Fjeldbo CS, Lyng H, Milosevic MF (2024)
An Immune Gene Expression Risk Score for Distant Metastases after Radiotherapy for Cervical Cancer
Clin Cancer Res, 30 (6), 1200-1207
DOI 10.1158/1078-0432.CCR-23-2085, PubMed 38180733

Publications 2023

Skingen VE, Hompland T, Fjeldbo CS, Salberg UB, Helgeland H, Ragnum HB, Aarnes EK, Vlatkovic L, Hole KH, Seierstad T, Lyng H (2023)
Prostate cancer radiogenomics reveals proliferative gene expression programs associated with distinct MRI-based hypoxia levels
Radiother Oncol, 188, 109875
DOI 10.1016/j.radonc.2023.109875, PubMed 37640161

Publications 2022

Chakravarthy A, Reddin I, Henderson S, Dong C, Kirkwood N, Jeyakumar M, Rodriguez DR, Martinez NG, McDermott J, Su X, Egawa N, Fjeldbo CS, Skingen VE, Lyng H, Halle MK, Krakstad C, Soleiman A, Sprung S, Lechner M, Ellis PJI, Wass M, Michaelis M, Fiegl H, Salvesen H, Thomas GJ et al. (2022)
Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance
Nat Commun, 13 (1), 5818
DOI 10.1038/s41467-022-33544-x, PubMed 36207323

Nilsen A, Hillestad T, Skingen VE, Aarnes EK, Fjeldbo CS, Hompland T, Evensen TS, Stokke T, Kristensen GB, Grallert B, Lyng H (2022)
miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer
Mol Oncol, 16 (6), 1402-1419
DOI 10.1002/1878-0261.13184, PubMed 35064630

Salberg UB, Skingen VE, Fjeldbo CS, Hompland T, Ragnum HB, Vlatkovic L, Hole KH, Seierstad T, Lyng H (2022)
A prognostic hypoxia gene signature with low heterogeneity within the dominant tumour lesion in prostate cancer patients
Br J Cancer, 127 (2), 321-328
DOI 10.1038/s41416-022-01782-x, PubMed 35332267

Publications 2021

Hompland T, Fjeldbo CS, Lyng H (2021)
Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter
Cancers (Basel), 13 (3)
DOI 10.3390/cancers13030499, PubMed 33525508

Publications 2020

Fjeldbo CS, Hompland T, Hillestad T, Aarnes EK, Günther CC, Kristensen GB, Malinen E, Lyng H (2020)
Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity
EBioMedicine, 57, 102841
DOI 10.1016/j.ebiom.2020.102841, PubMed 32580139

Hillestad T, Hompland T, Fjeldbo CS, Skingen VE, Salberg UB, Aarnes EK, Nilsen A, Lund KV, Evensen TS, Kristensen GB, Stokke T, Lyng H (2020)
MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer
Cancer Res, 80 (18), 3993-4003
DOI 10.1158/0008-5472.CAN-20-0950, PubMed 32606004

Publications 2019

Jonsson M, Fjeldbo CS, Holm R, Stokke T, Kristensen GB, Lyng H (2019)
Mitochondrial Function of CKS2 Oncoprotein Links Oxidative Phosphorylation with Cell Division in Chemoradioresistant Cervical Cancer
Neoplasia, 21 (4), 353-362
DOI 10.1016/j.neo.2019.01.002, PubMed 30856376

Publications 2016

Fjeldbo CS, Julin CH, Lando M, Forsberg MF, Aarnes EK, Alsner J, Kristensen GB, Malinen E, Lyng H (2016)
Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer
Clin Cancer Res, 22 (16), 4067-76
DOI 10.1158/1078-0432.CCR-15-2322, PubMed 27012812

Fjeldbo CS, Aarnes EK, Malinen E, Kristensen GB, Lyng H (2016)
Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer Patients
PLoS One, 11 (5), e0156259
DOI 10.1371/journal.pone.0156259, PubMed 27244197

Publications 2015

Lando M, Fjeldbo CS, Wilting SM, C Snoek B, Aarnes EK, Forsberg MF, Kristensen GB, Steenbergen RD, Lyng H (2015)
Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer
Epigenetics, 10 (10), 970-80
DOI 10.1080/15592294.2015.1085140, PubMed 26291246

Publications 2013

Selvik LK, Fjeldbo CS, Flatberg A, Steigedal TS, Misund K, Anderssen E, Doseth B, Langaas M, Tripathi S, Beisvag V, Lægreid A, Thommesen L, Bruland T (2013)
The duration of gastrin treatment affects global gene expression and molecular responses involved in ER stress and anti-apoptosis
BMC Genomics, 14, 429
DOI 10.1186/1471-2164-14-429, PubMed 23805861

Steigedal TS, Prestvik WS, Selvik LK, Fjeldbo CS, Bruland T, Lægreid A, Thommesen L (2013)
Gastrin-induced proliferation involves MEK partner 1 (MP1)
In Vitro Cell Dev Biol Anim, 49 (3), 162-9
DOI 10.1007/s11626-013-9588-2, PubMed 23408059

Publications 2011

Fjeldbo CS, Bakke I, Erlandsen SE, Holmseth J, Lægreid A, Sandvik AK, Thommesen L, Bruland T (2011)
Gastrin upregulates the prosurvival factor secretory clusterin in adenocarcinoma cells and in oxyntic mucosa of hypergastrinemic rats
Am J Physiol Gastrointest Liver Physiol, 302 (1), G21-33
DOI 10.1152/ajpgi.00197.2011, PubMed 21995960

Publications 2010

Fjeldbo CS, Misund K, Günther CC, Langaas M, Steigedal TS, Thommesen L, Laegreid A, Bruland T (2010)
Functional studies on RNA-transfected cell microarrays
Methods Mol Biol, 629, 175-91
DOI 10.1007/978-1-60761-657-3_12, PubMed 20387150

Publications 2008

Fjeldbo CS, Misund K, Günther CC, Langaas M, Steigedal TS, Thommesen L, Laegreid A, Bruland T (2008)
Functional studies on transfected cell microarray analysed by linear regression modelling
Nucleic Acids Res, 36 (15), e97
DOI 10.1093/nar/gkn428, PubMed 18628295